NewAmsterdam Pharma Company N.V (NAMS) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.28: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.32; Below-average business quality.
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates... Read more
Sell if holding. Engine safety override at $35.28: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.32; Below-average business quality. Chart setup: Trend continuation, RSI 68, MACD bullish. Score 5.0/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — NewAmsterdam Pharma Company N.V
Material events (past 30 days)
- Apr 24, 2026 MEDIUM Item 5.02: Louise Kooij, Chief Accounting Officer, agreed to depart effective August 31, 2026. Separation agreement includes 12 months base salary and pro-rated bonus. No successor named.
Latest news
- Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday — benzinga May 8, 2026 neutral
- NewAmsterdam Pharma Q1 EPS $(0.40) Beats $(0.47) Estimate, Sales $3.040M Beat $936.364K Estimate — benzinga May 7, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineobicetrapib10-K Item 1A: 'We are dependent on the success of our only product candidate, obicetrapib, and cannot guarantee that obicetrapib will successfully complete clinical development, receive regulatory approval'
Material Events(8-K, last 90d)
- 2026-04-24Item 5.02MEDIUMLouise Kooij, Chief Accounting Officer, agreed to depart effective August 31, 2026. Separation agreement includes 12 months base salary and pro-rated bonus. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.28: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.32; Below-average business quality. Chart setup: Trend continuation, RSI 68, MACD bullish. Prior stop was $32.93. Score 5.0/10, moderate confidence.
Take-profit target: $43.47 (+22.8% upside). Prior stop was $32.93. Stop-loss: $32.93.
Concentration risk — Pipeline: obicetrapib; Quality below floor (3.1 < 4.0).
NewAmsterdam Pharma Company N.V trades at a P/E of N/A (forward -26.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
22 analysts cover NAMS with a consensus score of 4.3/5. Average price target: $50.
What does NewAmsterdam Pharma Company N.V do?NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for...
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients. The company has no approved products and generates no product revenue; it is funded through equity and operates at a net loss ($203.8M in 2025).